Navigation Links
Hepatitis B virus reemerges with long-term nucleoside analog treatment
Date:4/27/2011

A recently published study revealed that virological breakthrough (VBT) is common in patients receiving nucleoside analogs (NUCs) for chronic hepatitis B. Nearly 40% of the VBTs found were not related to antiviral drug resistance. Details of this retrospective study are published in the May issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

VBT is the first manifestation of antiviral drug resistance during NUC therapy of chronic hepatitis B. NUC drugs approved for treatment of chronic hepatitis B include lamivudine (LAM), adefovir (ADV), entecavir (ETV), telbivudine (TBV), and tenofovir (TDF). While the medications suppress the virus with few side effects, they do not eradicate HBV and require long-term treatment to provide clinical benefit. With long-term NUC therapy, studies have shown an increasing risk of drug resistance particularly with monotherapy regimens.

In the current study, Anna Lok, M.D. and colleagues from the University of Michigan Health System examined the incidence of VBT and genotypic resistance (GR) in 148 patients with chronic hepatitis B who were treated with NUCs between January 2000 and July 2010. The mean age of study participants was 45 years and 73% were male. Researchers reviewed medical records and recorded patient demographics, hepatitis B virus (HBV) markers, liver panel, blood counts and liver histology.

Results showed that during a mean follow-up of 38 months, 39 (26%) patients had at least one VBT, and upon retesting, 15 (38%) of these patients did not have a VBT and 10 had no evidence of GR. Researchers reported the probability of VBT, confirmed VBT, and GR at five years was 46%, 30%, and 34%, respectively. "Our analysis showed an alarmingly high rate of VBT in clinical practice and the only factor significantly linked to VBT was failure to achieve undectectable HBV DNA," said Dr. Lok.

HBV DNA decreased
'/>"/>

Contact: Dawn Peters
healthnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Page: 1 2

Related medicine news :

1. New screening system for hepatitis C
2. Groundbreaking research to find vaccine for hepatitis C
3. 1 in 5 At-Risk U.S. Babies Doesnt Get Hepatitis B Vaccine
4. Vaccination, Prevention Is Beating Back Hepatitis
5. Bipartisan Capitol Hill Media Event: Health Experts, Lawmakers to Urge Federal Government to Fix the Funding Failure for Chronic Viral Hepatitis
6. Hepatitis C treatment less effective in urban minority patients
7. Researchers identify potential new target for treating hepatitis C
8. Donor kidneys from Hepatitis C patients needlessly denied to patients with that infection
9. Henry Ford Hospital atudy: Hepatitis C infection doubles risk for kidney cancer
10. New Drug Shows Promise for Curing Hepatitis C
11. Hepatitis C Tied to Higher Kidney Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Carinsurancesavings.biz has released a ... death and dismemberment insurance . , Purchasing an accidental ... be very advantageous. This type of rider provides benefits if ... can be considered a lesser form of life insurance. ...
(Date:1/22/2015)... Jolla, Calif. (PRWEB) January 22, 2015 ... Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) ... for their leadership in advancing biotechnology, biomedical science, ... Bonilla and Olsen each received the “2014 Life ...
(Date:1/22/2015)... Four years since the release of their debut recording Love ... of Avasa & Matthew Love – the duo are pleased to ... through White Swan Records on February 24, 2015. , THE ROAD ... available to all of us to walk out of the mire ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 As ... of overall health care gains momentum worldwide, Rev. Eric ... HealthCare Chaplaincy Network (HCCN), will be the keynote ... spiritual care in Israel’s public health system. , The conference, ...
(Date:1/22/2015)... released a new blog post explaining the importance of keeping a ... of an auto insurance policy . , Clients who driver ... their vehicle insurance policies. The safety a vehicle offers from its ... of this, drivers should always carry a first aid kit in ...
Breaking Medicine News(10 mins):Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... - Adjusted Diluted EPS (1) was $0.42 -- Annual Guidance Narrowed to $2.05 to $2.18 Adjusted Diluted ... West Pharmaceutical Services, Inc. (NYSE: WST ) today announced its results for the first quarter ... Three Months Ended, ... ...
... April 30 Quigley Pharma Inc., www.quigleyco.com ... Corporation (Nasdaq: QGLY ) announced today that ... of diabetic peripheral neuropathy, demonstrated a significant improvement in ... the group treated with QR333. The compound was ...
... PARK CITY, Utah, April 30 Nutraceutical International Corporation (Nasdaq: ... 2009 second quarter ended March 31, 2009. Net sales ... to $44.4 million for the same quarter of fiscal 2008.Primarily ... recession and the related turmoil in the equity markets, there ...
... Gentiva Health Services, Inc. (Nasdaq: GTIV ), ... the following 2009 first quarter results: , ... revenues of $288.9 million for the quarter ended March 29, ... $77.8 million from its CareCentrix business unit, for the quarter ...
... April 3 In conjunction with its first quarter 2009 earnings ... 2009), Covance Inc. (NYSE: CVD ) is pleased to ... will be broadcast live over the Internet on Thursday, April 30, ... First Quarter 2009 Earnings Webcast and Slide Presentation, ...
... increases 9 percent to $24.9 billion- GAAP earnings from ... decrease 10 percent to $350 million on a non-GAAP ... decline 15 percent to $0.87 and decrease 10 percent ... Cardinal Health, a global provider of products and ...
Cached Medicine News:Health News:West Announces First Quarter 2009 Results 2Health News:West Announces First Quarter 2009 Results 3Health News:West Announces First Quarter 2009 Results 4Health News:West Announces First Quarter 2009 Results 5Health News:West Announces First Quarter 2009 Results 6Health News:West Announces First Quarter 2009 Results 7Health News:West Announces First Quarter 2009 Results 8Health News:West Announces First Quarter 2009 Results 9Health News:West Announces First Quarter 2009 Results 10Health News:West Announces First Quarter 2009 Results 11Health News:West Announces First Quarter 2009 Results 12Health News:West Announces First Quarter 2009 Results 13Health News:West Announces First Quarter 2009 Results 14Health News:West Announces First Quarter 2009 Results 15Health News:West Announces First Quarter 2009 Results 16Health News:West Announces First Quarter 2009 Results 17Health News:West Announces First Quarter 2009 Results 18Health News:Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification 2Health News:Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification 3Health News:Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; Findings Suggest Possible Disease Modification 4Health News:Nutraceutical Reports Fiscal 2009 Q2 Results 2Health News:Nutraceutical Reports Fiscal 2009 Q2 Results 3Health News:Nutraceutical Reports Fiscal 2009 Q2 Results 4Health News:Nutraceutical Reports Fiscal 2009 Q2 Results 5Health News:Nutraceutical Reports Fiscal 2009 Q2 Results 6Health News:Nutraceutical Reports Fiscal 2009 Q2 Results 7Health News:Nutraceutical Reports Fiscal 2009 Q2 Results 8Health News:Gentiva Reports First Quarter 2009 Results 2Health News:Gentiva Reports First Quarter 2009 Results 3Health News:Gentiva Reports First Quarter 2009 Results 4Health News:Gentiva Reports First Quarter 2009 Results 5Health News:Gentiva Reports First Quarter 2009 Results 6Health News:Gentiva Reports First Quarter 2009 Results 7Health News:Gentiva Reports First Quarter 2009 Results 8Health News:Gentiva Reports First Quarter 2009 Results 9
(Date:1/23/2015)... Rose, baseball,s all-time hits leader, is the new spokesperson for ... Pharma has announced. "Pete,s a Hall of Famer ... on board with Myoflex," said Ducere Pharma Chief Executive Officer ... is known across all generations. The passion and intensity that ...
(Date:1/23/2015)... Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced ... trial of Lixte,s lead compound, LB‑100, is being conducted, has ... John S. Kovach , M.D., the founder and President of ... completed at a single site. Accrual of patients, however, was ...
(Date:1/23/2015)...  Mallinckrodt plc (NYSE: MNK ) announced today ... repurchase program. The open-ended authorization permits the company to ... shares. "Funding additional initiatives and seeking ... continue to pursue a range of focused growth strategies," ...
Breaking Medicine Technology:Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... 2, 2011 Reportlinker.com announces ... report is available in its ... Cardiology Devices: World Market Prospects ... http://www.reportlinker.com/p0663863/Interventional-Cardiology-Devices-World-Market-Prospects-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine Our ...
... 2, 2011 Syndax Pharmaceuticals, Inc ., a ... in a subset of patients from ENCORE 301, a ... entinostat in advanced breast cancer patients, will be presented ... for Cancer Research (AACR) Molecular Targets and Cancer Therapeutics ...
Cached Medicine Technology:Interventional Cardiology Devices: World Market Prospects 2011-2021 2Interventional Cardiology Devices: World Market Prospects 2011-2021 3Interventional Cardiology Devices: World Market Prospects 2011-2021 4Interventional Cardiology Devices: World Market Prospects 2011-2021 5Interventional Cardiology Devices: World Market Prospects 2011-2021 6Interventional Cardiology Devices: World Market Prospects 2011-2021 7Interventional Cardiology Devices: World Market Prospects 2011-2021 8Interventional Cardiology Devices: World Market Prospects 2011-2021 9Interventional Cardiology Devices: World Market Prospects 2011-2021 10Interventional Cardiology Devices: World Market Prospects 2011-2021 11Interventional Cardiology Devices: World Market Prospects 2011-2021 12Interventional Cardiology Devices: World Market Prospects 2011-2021 13Interventional Cardiology Devices: World Market Prospects 2011-2021 14Pharmacodynamic Data from Syndax Pharmaceutical's ENCORE 301 Study in Advanced Breast Cancer to be Highlighted at the AACR Molecular Targets and Cancer Therapeutics Conference 2011 2Pharmacodynamic Data from Syndax Pharmaceutical's ENCORE 301 Study in Advanced Breast Cancer to be Highlighted at the AACR Molecular Targets and Cancer Therapeutics Conference 2011 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: